NASDAQ:PRVB

SHAREHOLDER ALERT: Morris Kandinov Investigating PRVB, MAXR, DNA, and FOX; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Wednesday, March 29, 2023
Advent International, Sanofi, Ginkgo Bioworks, SAN, Advertising, Maxar Technologies, Fox Corporation, Real estate

If you are a current owner of shares, contact [email protected] or call (619) 780-3993 to speak with attorney Leo Kandinov.

Key Points: 
  • If you are a current owner of shares, contact [email protected] or call (619) 780-3993 to speak with attorney Leo Kandinov.
  • Morris Kandinov is investigating possible breaches of fiduciary duties and other violations of law related to Provention Bio, Inc.’s agreement to be acquired by Sanofi.
  • Under the terms of the agreement Provention Bio’s shareholders will receive $25 per share in cash.
  • Concerned shareholders are encouraged to contact Leo Kandinov to learn more:
    Morris Kandinov LLP is a national law firm that specializes in recovering investment losses and protecting stockholder rights.

PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

Retrieved on: 
Wednesday, March 29, 2023
Class Action Lawsuit, Professional Services, Legal, KSF, Sale, Sanofi

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi (NasdaqGS: SNY).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi (NasdaqGS: SNY).
  • Under the terms of the proposed transaction, shareholders of Provention will receive only $25.00 in cash for each share of Provention that they own.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

Retrieved on: 
Thursday, March 23, 2023
Tripura Merger Agreement, HNI, Brodsky, PFE, CVS, Pfizer, HNI Corporation, Oak Street Health, SNY, NYSE, Security (finance), Seagen, Sanofi

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the deal, Oak Street Health will be acquired by CVS Health® (“CVS”) (NYSE - CVS).
  • Oak Street Health stockholders will receive $39.00 per share in an all-cash transaction, representing an enterprise value of approximately $10.6 billion.
  • Kimball shareholders will receive $9.00 in cash and 0.1301 shares of HNI common stock for each share of Kimball common stock they own.

Moore Kuehn Encourages RADI, PRVB, CVT, and UNVR Investors to Contact Law Firm

Retrieved on: 
Tuesday, March 21, 2023
Blackstone, Sanofi, PLLC, Wall Street, Fraud, Univar Solutions, QT, Security (finance), Bank

Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.

Key Points: 
  • Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
  • Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq.
  • Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
  • Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, ADAP, PRVB, XM

Retrieved on: 
Sunday, March 19, 2023
Pfizer, Sale, Silver, In re Caremark International Inc. Derivative Litigation, Advertising, Qualtrics, Fraud, Therapy, Security (finance), Seagen, Sanofi

If you are a Seagen shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Seagen shareholder, click here to learn more about your rights and options .
  • If you are a Adaptimmune shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Lifshitz Law PLLC Announces Investigations of SGEN, PRVB, KBAL, and ADAP

Retrieved on: 
Sunday, March 19, 2023
Therapy, ADAP, HNI, Telephone, PLLC, Pfizer, Sale, Advertising, HNI Corporation, KBAL, Hewlett, Online shopping

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SGEN to Pfizer Inc. for $229.00 per share in cash.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SGEN to Pfizer Inc. for $229.00 per share in cash.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of PRVB to Sanofi S.A. for $25.00 per share in cash.
  • Lifshitz L aw PLLC announces investigation into possible breach of fiduciary duties in connection with the merger of ADAP and TCR² Therapeutics, Inc.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?

Retrieved on: 
Friday, March 17, 2023
Learning, LLP, SAN, Acquisition, Type 1, Patient, T1D, Sale, Pharmaceutical industry, Sanofi

SAN DIEGO, March 17, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Provention Bio Inc. (Nasdaq - PRVB) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (Nasdaq – SNY).

Key Points: 
  • SAN DIEGO, March 17, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Provention Bio Inc. (Nasdaq - PRVB) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (Nasdaq – SNY).
  • On March 13, 2023, Provention announced that it has entered into a definitive agreement to be acquired by Sanofi, in an all-cash transaction; Provention stockholders would receive $25.00 per share in cash.
  • Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given the $9.6 billion estimated global market opportunity for Type 1 diabetes drugs by 2030.
  • If you are a shareholder of Provention and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact lead analyst Jim Baker ( [email protected] ) at 619-814-4471.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, XM, PRVB, SGEN

Retrieved on: 
Wednesday, March 15, 2023
Acquisition, Monteverde, Moran v. Household International, Inc., Sale, First Bank, Qualtrics, Silver, XM, Pfizer, Empire, Seagen, Security (finance), Sanofi

Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.
  • Under the terms of the agreement XM shareholders are expected to receive $18.15 in cash per share they own.
  • Under the terms of the agreement PRVB shareholders are expected to receive $25.00 in cash per share they own.
  • Under the terms of the agreement SGEN shareholders are expected to receive $229.00 in cash per share they own.

Moore Kuehn Encourages XM, OSH, SGEN, and PRVB Investors to Contact Law Firm

Retrieved on: 
Tuesday, March 14, 2023
Wall Street, Sanofi, PLLC, Fraud, Oak Street Health, Oak Street, Silver, Pfizer, Health, CVS Health, Security (finance), Bank, Qualtrics, Seagen

Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.

Key Points: 
  • Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
  • Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq.
  • Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
  • Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates PRVB, SGEN, XM

Retrieved on: 
Tuesday, March 14, 2023
In re Caremark International Inc. Derivative Litigation, Qualtrics, Sale, Fraud, Silver, Pfizer, Advertising, Security (finance), Sanofi, Seagen

If you are a Provention shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Provention shareholder, click here to learn more about your rights and options .
  • If you are a Seagen shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.